Skip to main content

Want a detailed portfolio tracker?

Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2026)

Aquestive Therapeutics (AQST) free cash flow from Jun 30, 2017 to Mar 31, 2026. The TTM Aquestive Therapeutics (AQST) free cash flow is -$44M. You can adjust inflation or export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual Free Cash Flow

Quarterly Free Cash Flow

Aquestive Therapeutics (AQST) Free Cash Flow CAGR table

PeriodCAGR
1 Year TTM-9.64%
5 Years TTM-0.91%

Annual Free Cash Flow change of Aquestive Therapeutics (AQST)

YearFree Cash FlowChange
2026-$15M-71.96%
2025-$53M+47.52%
2024-$36M+386.72%
2023-$7.38M-31.73%
2022-$11M-68.10%
2021-$34M-26.29%
2020-$46M-24.46%
2019-$61M+311.01%
2018-$15M-494.93%
2017$3.75MN/A

Comparison Aquestive Therapeutics (AQST) five years free cash flow CAGR with competitors

Aquestive Therapeutics (AQST) five years free cash flow CAGR is -0.92%.